Journal
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
Volume 74, Issue 6, Pages 272-274Publisher
ELSEVIER TAIWAN
DOI: 10.1016/j.jcma.2011.04.007
Keywords
GIST; Imatinib-resistant; kit mutation; Pegylated liposomal doxorubicin
Categories
Ask authors/readers for more resources
Here we presented a 60-year-old Taiwanese man with advanced gastrointestinal stromal tumor. Disease progression was noted during imatinib treatment. Surgical resection was done and mutation analysis of KIT gene in all the resected tumors revealed deletion mutations of codons 558-565 in exon 11, whereas a missense mutation was also identified at codon 822 in exon 17 in one resected tumor. Patient's disease was refractory to escalating dose of imatinib and dasatinb. Surprisingly, combination of imatinib with pegylated liposomal doxorubicin produced a substantial response and resulted in a 5-month progression free period for this imatinib-resistant gastrointestinal stromal tumor. Copyright (C) 2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available